Neurogene Appoints Industry Veteran Robert A. Baffi, Ph.D. to Board of Directors

Dr. Baffi brings more than 30 years of manufacturing and drug development experience to support the advancement of Neurogene’s gene therapy pipeline into the clinic

NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by neurological diseases, today announced Robert A. Baffi, Ph.D. will join its board of directors. Dr. Baffi has extensive experience in biologics and gene therapy manufacturing, drug development, and global regulatory approvals, and his support will help Neurogene develop and accelerate its GMP (Good Manufacturing Practice) capabilities.

“Robert’s expertise in building and scaling gene therapy production will be an invaluable resource for Neurogene as we prepare to enter the clinic and plan for future product development and approvals,” said Rachel McMinn, Ph.D., Neurogene Founder and Chief Executive Officer. “Moreover, his understanding of and passion for developing treatments for diseases with no available treatment options aligns with our mission. We are pleased to welcome him to the board.”

Dr. Baffi brings more than 30 years of biologics manufacturing experience, including pioneering and establishing innovative methods for large-scale, high-yielding gene therapy production. He has contributed to more than 25 regulatory submissions for product approvals in the United States, Europe and Japan, along with more than 50 regulatory submissions for investigational new drug testing. Dr. Baffi served as President of Global Manufacturing & Technical Operations at BioMarin Pharmaceutical Inc., where he spent 20 years in various capacities overseeing the manufacturing, process development, quality, analytical chemistry, logistics and engineering departments. Prior to BioMarin, Dr. Baffi worked for Genentech, Cooper BioMedical and Becton Dickinson Research Center. He currently serves on the board for the National Institute for Bioprocessing Research & Training (NIBRT). Dr. Baffi received a Ph.D., M. Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

“I’ve been fortunate in my career to be involved in the development of manufacturing and quality strategies leading to the approval of products that provided benefits to patients suffering from devastating diseases,” said Dr. Robert Baffi. “Neurogene’s mission to develop genetic therapies for people and families affected by neurological diseases is an area of significant unmet medical need, and I am looking forward to putting my experience into service as a member of Neurogene’s board of directors.”

About Neurogene Inc.

Neurogene Inc. is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs are designed to use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.